Literature DB >> 15505753

Neuroimaging trials of Parkinson's disease progression.

John Seibyl1, Danna Jennings, Rowena Tabamo, Ken Marek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15505753     DOI： 10.1007/s00415-004-1704-5

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  25 in total

Review 1.  SPECT and PET imaging of the dopaminergic system in Parkinson's disease.

Authors:  T Brücke; S Djamshidian; G Bencsits; W Pirker; S Asenbaum; I Podreka
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

2.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Authors:  K Marek; R Innis; C van Dyck; B Fussell; M Early; S Eberly; D Oakes; J Seibyl
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

3.  A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group.

Authors: 
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

4.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

5.  Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Authors:  R B Innis; K L Marek; K Sheff; S Zoghbi; J Castronuovo; A Feigin; J P Seibyl
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

6.  Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.

Authors:  J Booij; P Bergmans; A Winogrodzka; J D Speelman; E C Wolters
Journal:  Synapse       Date:  2001-02       Impact factor: 2.562

Review 7.  Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

Authors:  S Fahn
Journal:  Arch Neurol       Date:  1999-05

8.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

Authors: 
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

9.  Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT.

Authors:  W Staffen; A Mair; J Unterrainer; E Trinka; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

10.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422
View more
  6 in total

Review 1.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts.

Authors:  Oliver Pogarell; Walter Koch; Franz J Gildehaus; Andreas Kupsch; Olle Lindvall; Wolfgang H Oertel; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-27       Impact factor: 9.236

3.  Doppler sonography characteristics of vertebrobasilar circulation in patients with Parkinson's disease.

Authors:  Mirjana Vidović; Osman Sinanović; Dzevdet Smajlović; Adnan Burina; Josip Hudić
Journal:  Bosn J Basic Med Sci       Date:  2008-08       Impact factor: 3.363

4.  Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study.

Authors:  Yu Zhang; I-Wei Wu; Duygu Tosun; Eric Foster; Norbert Schuff
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

Review 5.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

6.  Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes.

Authors:  Roxana G Burciu; Jae Woo Chung; Priyank Shukla; Edward Ofori; Hong Li; Nikolaus R McFarland; Michael S Okun; David E Vaillancourt
Journal:  Neurology       Date:  2016-07-15       Impact factor: 9.910
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.